James Premdoss Clement

Dr. James Premdoss Clement

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2012 in Cell
Verified
Journal Article
Closed access
JCJames Premdoss Clement
James Premdoss Clement
MAMassimiliano Aceti
Massimiliano Aceti
TCThomas K. Creson
Thomas K. Creson
EOEmin D. Ozkan
Emin D. Ozkan
YSYulin Shi
Yulin Shi
GRGavin Rumbaugh
Gavin Rumbaugh

3 February 2006 in Science
Verified
Journal Article
Closed access
PDF file
RRRaghav Rajan
Raghav Rajan
JCJames Premdoss Clement
James Premdoss Clement
UBUpinder S. Bhalla
Upinder S. Bhalla
It has been hypothesized that rats and other mammals can use stereo cues to localize odor sources, but there is limited behavioral evidence to support this hypothesis. We found that rats trained on an odor-localization task can localize odors accurately in one or two sniffs. Bilateral sampling was essential for accurate odor localization, with internasal intensity and timing differences as directional cues. If the stimulus arrived at the correct point of the respiration cycle, internasal timing differences as short as 50 milliseconds sufficed. Neuronal recordings show that bulbar neurons responded differentially to stimuli from the left and stimuli from the right.

15 February 2016 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
PDF file
NJNallathambi Jeyabalan
Nallathambi Jeyabalan
JCJames Premdoss Clement
James Premdoss Clement
A cardinal feature of early stages of human brain development centres on the sensory, cognitive, and emotional experiences that shape neuronal-circuit formation and refinement. Consequently, alterations in these processes account for many psychiatric and neurodevelopmental disorders. Neurodevelopment disorders affect 3-4% of the world population. The impact of these disorders presents a major challenge to clinicians, geneticists, and neuroscientists. Mutations that cause neurodevelopmental disorders are commonly found in genes encoding proteins that regulate synaptic function. Investigation of the underlying mechanisms using gain or loss of function approaches has revealed alterations in dendritic spine structure, function, and plasticity, consequently modulating the neuronal circuit formation and thereby raising the possibility of neurodevelopmental disorders resulting from synaptopathies. One such gene, SYNGAP1 (Synaptic Ras-GTPase-activating protein has been shown to cause Intellectual Disability with comorbid Autism Spectrum Disorder and epilepsy in children. SYNGAP1 is a negative regulator of Ras, Rap and of AMPA receptor trafficking to the postsynaptic membrane, thereby regulating not only synaptic plasticity, but also neuronal homeostasis. Recent studies on the neurophysiology of SYNGAP1, using Syngap1 mouse models, have provided deeper insights into how downstream signalling proteins and synaptic plasticity are regulated by SYNGAP1. This knowledge has led to a better understanding of the function of SYNGAP1 and suggests a potential target during critical period of development when the brain is more susceptible to therapeutic intervention.

19 June 2013 in Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
JCJames Premdoss Clement
James Premdoss Clement
EOEmin D. Ozkan
Emin D. Ozkan
MAMassimiliano Aceti
Massimiliano Aceti
CMCourtney A. Miller
Courtney A. Miller
GRGavin Rumbaugh
Gavin Rumbaugh
Critical periods of developmental plasticity contribute to the refinement of neural connections that broadly shape brain development. These windows of plasticity are thought to be important for the maturation of perception, language, and cognition. Synaptic properties in cortical regions that underlie critical periods influence the onset and duration of windows, although it remains unclear how mechanisms that shape synapse development alter critical-period properties. In this study, we demonstrate that inactivation of a single copy of syngap1, which causes a surprisingly common form of sporadic, non-syndromic intellectual disability with autism in humans, induced widespread early functional maturation of excitatory connections in the mouse neocortex. This accelerated functional maturation was observed across distinct areas and layers of neocortex and directly influenced the duration of a critical-period synaptic plasticity associated with experience-dependent refinement of cortical maps. These studies support the idea that genetic control over synapse maturation influences the duration of critical-period plasticity windows. These data also suggest that critical-period duration links synapse maturation rates to the development of intellectual ability.

12 June 2019 in Open Biology
Verified
Journal Article
Open access
VVVijaya Verma
Vijaya Verma
APAbhik Paul
Abhik Paul
AVAnjali Amrapali Vishwanath
Anjali Amrapali Vishwanath
BVBhupesh Vaidya
Bhupesh Vaidya
JCJames Premdoss Clement
James Premdoss Clement
Normal brain development is highly dependent on the timely coordinated actions of genetic and environmental processes, and an aberration can lead to neurodevelopmental disorders (NDDs). Intellectual disability (ID) and autism spectrum disorders (ASDs) are a group of co-occurring NDDs that affect between 3% and 5% of the world population, thus presenting a great challenge to society. This problem calls for the need to understand the pathobiology of these disorders and to design new therapeutic strategies. One approach towards this has been the development of multiple analogous mouse models. This review discusses studies conducted in the mouse models of five major monogenic causes of ID and ASDs:Fmr1, Syngap1, Mecp2, Shank2/3andNeuroligins/Neurnexins.These studies reveal that, despite having a diverse molecular origin, the effects of these mutations converge onto similar or related aetiological pathways, consequently giving rise to the typical phenotype of cognitive, social and emotional deficits that are characteristic of ID and ASDs. This convergence, therefore, highlights common pathological nodes that can be targeted for therapy. Other than conventional therapeutic strategies such as non-pharmacological corrective methods and symptomatic alleviation, multiple studies in mouse models have successfully proved the possibility of pharmacological and genetic therapy enabling functional recovery.

20 June 2017 in Autophagy
Verified
Journal Article
Open access
SSS. N. Suresh
S. N. Suresh
ACAravinda K. Chavalmane
Aravinda K. Chavalmane
VDVidyadhara Dj
Vidyadhara Dj
HYHaorei Yarreiphang
Haorei Yarreiphang
SRShashank Rai
Shashank Rai
RMRavi Manjithaya
Ravi Manjithaya
Parkinson disease (PD) is a life-threatening neurodegenerative movement disorder with unmet therapeutic intervention. We have identified a small molecule autophagy modulator, 6-Bio that shows clearance of toxic SNCA/α-synuclein (a protein implicated in synucleopathies) aggregates in yeast and mammalian cell lines. 6-Bio induces autophagy and dramatically enhances autolysosome formation resulting in SNCA degradation. Importantly, neuroprotective function of 6-Bio as envisaged by immunohistology and behavior analyses in a preclinical model of PD where it induces autophagy in dopaminergic (DAergic) neurons of mice midbrain to clear toxic protein aggregates suggesting that it could be a potential therapeutic candidate for protein conformational disorders.